Écrit par Pierre Fabre | 09 Novembre 2016

Binimetinib plus encorafenib meets primary endpoint with statistically significant advantage on median PFS of 14.9 months versus 7.3 months for vemurafenib monotherapy. Additional PFS, ORR and durability data support primary endpoint result

Detailed safety and drug exposure data presented; combination of binimetinib plus encorafenib demonstrates a favorable tolerability profile

Castres...

Écrit par InterSystemsInterSystems | 09 Novembre 2016

InterSystems au cœur des améliorations de la qualité des soins prodigués au patient pour les 45.000 habitants des iles écossaises




Paris, le 9 Novembre 2016 - Grâce à la solution TrakCare d'InterSystems, les 45.000 habitants des Iles écossaises Shetland et Orknet vont bénéficier d'un nouveau système de partage des informations médicales et avoir accès au système...

Écrit par Novozymes | 09 Novembre 2016

Novozymes Fermax™ is an enzyme that replaces chemicals in the sugarcane ethanol production process.


COPENHAGEN, Denmark – November 8, 2016 –  Today, Novozymes launches Fermax, an enzyme protease that prevents foam development during the sugarcane ethanol fermentation process, while delivering improved control and replacing chemicals. For an average size plant, trialing partners also...

Écrit par GlobalData | 09 Novembre 2016

London – 8 November 2016 - Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according to research and consulting firm GlobalData.

As explored in GlobalData’s most recent MDD report, ALKS-5461 is one of six late-stage pipeline products showing promise with regards to improving...